Biogen Inc (BIIB)

BIIB (NASDAQ:Drugs) EQUITY
$295.61
pos +12.65
+4.47%
Today's Range: 285.02 - 296.95 | BIIB Avg Daily Volume: 1,484,700
Last Update: 07/26/17 - 4:14 PM EDT
Volume: 2,954,568
YTD Performance: 8.27%
Open: $288.55
Previous Close: $282.96
52 Week Range: $223.02 - $338.51
Oustanding Shares: 212,115,203
Market Cap: 60,389,198,294
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 10 9 9
Moderate Buy 0 0 0 0
Hold 7 6 6 8
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.88 1.75 1.80 1.94
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 17.84
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
17.84 16.80 31.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-1.37% 6.85% -8.47%
GROWTH 12 Mo 3 Yr CAGR
Revenue 10.80 0.70 0.18
Net Income 2.90 1.00 0.25
EPS 10.40 1.20 0.29
Earnings for BIIB:
EBITDA 4.28B
Revenue 10.13B
Average Earnings Estimates
Qtr (09/17) Qtr (12/17) FY (12/17) FY (12/18)
Average Estimate $5.35 $5.43 $21.10 $22.66
Number of Analysts 21 21 3 23
High Estimate $5.74 $6.01 $21.12 $24.97
Low Estimate $4.91 $4.76 $21.08 $19.73
Prior Year $5.19 $5.04 $20.22 $21.10
Growth Rate (Year over Year) 3.06% 7.79% 4.34% 7.43%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Bullish
Jul 26, 2017 | 9:07 AM EDT
Goldman Sachs upgraded Biogen to "Buy" from "Neutral" with a $338 price target.
These disparate names seem to fit quite well with the investment approach of the Oracle of Omaha.

Biogen Ready for a Big Bounce Real Money Pro($)

The chart shows this stock has bottomed.
We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.
The market rally broadened out nicely today.

Charting the Biotechs Real Money Pro($)

Time to revisit some stocks now that biotech has cooled.
* Biotech (Allergan (AGN) , Celgene (CELG) and Gilead Sciences (GILD) ) * Speculative biotech ( ZIOPHARM Oncology (ZIOP) ,   SAGE Therapeutics (SAGE) , Intrexon (XON) , Valeant Pharmaceuticals (VRX) ,   ACADIA Pharmaceuticals (ACAD) , FibroGen  (FGEN) ). * DuPont (DD) , Netflix (NFLX) , Baidu (BIDU) , Radian (RDN) and Biogen   (BIIB) . * New tech - (T)FANG (TSLA) , (FB) , (AAPL) , (NFLX) , (GOOGL) . * Chipotle Mexican Grill (
Many want to undo what's been done, but not enough to send the market down.
Bearish
Mar 16, 2017 | 7:13 AM EDT
BIIB was downgraded from Outperform to Market Perform, Leerink Partners said. $300 price target. Spinraza checks suggest a slow start.
There are nearly too many surging sectors to count.

Columnist Conversations

we'll take this nice winner off the table SOLD ADSK AUG 105 CALL AT 9 (in at 4.45)
COST is beginning to firm up near the $150.00 area. The stock bottomed here at last December's lows before exp...
We like this move today on good turnover and strong option flow. BOUGHT FCX OCT 15 CALL AT 1.04
View Chart »  View in New Window » So far we are holding key support in this one.  Target...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.